PDX Portal

PDX INSIGHTS

PIONEERING CANCER RESEARCH

Sarcoma Collection

Collection Summaries:

Collection Details:

Search All Columns:

Model IDFilter by Model ID	Patient IDFilter by Patient ID	Pathology Diagnosis	Race	Age at Diagnosis	Gender	Germline TP53Filter by Germline TP53	Treatment NaiveFilter by Treatment Naive	Survival in MonthsFilter by Survival in Months	Time of Collection	Disease Stage at Diagnosis			Patient TreatmentFilter by Patient Treatment
Model IDFilter by Model ID	Patient IDFilter by Patient ID	Pathology Diagnosis	Race	Age at Diagnosis	Gender	Germline TP53Filter by Germline TP53	Treatment NaiveFilter by Treatment Naive	Survival in MonthsFilter by Survival in Months	Time of Collection	Bone Sarcoma StageFilter by Bone Sarcoma Stage	Rhabdomyosarcoma RiskFilter by Rhabdomyosarcoma Risk	NRSTS StageFilter by NRSTS Stage	Patient TreatmentFilter by Patient Treatment
TCCC-EWS82	TCH018	Ewing Sarcoma	White	14.91	Female	Not Performed	Yes	42	Diagnosis	Bone Sarcoma StageFilter by Bone Sarcoma Stage	Rhabdomyosarcoma RiskFilter by Rhabdomyosarcoma Risk	NRSTS StageFilter by NRSTS Stage	Metastatic			Cyclophosphamide,Doxorubicin,Etoposide,Ifosfamide,Vicristine
TCCC-OS13	TCH001	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	11.41	Female	Not Performed	No	21	Local Control	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate
TCCC-OS14	TCH002	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	15.75	Male	Negative	Yes	39	Diagnosis	Metastatic			Cisplatin,Doxorubicin,Investigational agent,Methotrexate,Palliative
TCCC-OS18	TCH003	Osteosarcoma(Osteoblastic)	White	13.75	Female	Negative	Yes	65	Diagnosis	Localized			Cisplatin,Doxorubicin,Methotrexate
TCCC-OS22	TCH004	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	14.0	Female	Negative	No	66	Local Control	Localized			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate
TCCC-OS23	TCH005	NRSTS(Others)	White,Hispanic or Latino	13.75	Female	Not Performed	Yes	5	Diagnosis			IV	Cisplatin,Doxorubicin,Methotrexate
TCCC-OS32	TCH006+	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	14.5	Female	Not Performed	No	12	Local Control	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Investigational agent,Methotrexate,Palliative
TCCC-OS39	TCH006+	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	14.5	Female	Not Performed	No	12	Metastasis	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Investigational agent,Methotrexate,Palliative
TCCC-OS45	TCH007	Osteosarcoma(Telangiectatic)	White,Hispanic or Latino	15.66	Male	Not Performed	No	73	Metastasis	Localized			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate
TCCC-OS46	TCH008	Osteosarcoma(Osteoblastic)	White	14.25	Male	Not Performed	Yes	53	Diagnosis	Localized			Cisplatin,Doxorubicin,Methotrexate
TCCC-OS51	TCH009+	Osteosarcoma(Osteoblastic)	White	8.0	Female	Not Performed	Yes	22	Diagnosis	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate
TCCC-OS52	TCH009+	Osteosarcoma(Osteoblastic)	White	8.0	Female	Not Performed	Yes	22	Diagnosis	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate
TCCC-OS54	TCH010+	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	18.16	Male	Not Performed	Yes	14	Diagnosis	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Investigational agent,Methotrexate,Palliative
TCCC-OS57	TCH011	Osteosarcoma(Osteoblastic)	Black or African American	16.16	Male	Not Performed	Yes	49	Diagnosis	Localized			Cisplatin,Doxorubicin,Methotrexate
TCCC-OS63	TCH012+	Osteosarcoma(Osteoblastic)	White,Hispanic or Latino	10.66	Male	Positive	Yes	12	Diagnosis	Metastatic			Cisplatin,Doxorubicin,Etoposide,Ifosfamide,Methotrexate

* indicates the model is private.
+ indicates the patient has multiple models.

SITE LINKS

Collections
Omics Tools
Publications
Our Team
Contact Us

COLLECTIONS

Bladder Breast Leukemia Liver Pancreas Sarcoma

CONTACT

PDX Development Unit
BCM PDX Core
PDX Pediatric Liver Program
Baylor College of Medicine

SUPPORTED BY

Cancer Prevention and Research
Institute of Texas (RP220646)

Dan L Duncan Cancer Center (P30 Cancer Center Support Grant NCI-CA125123)
Advanced Technology Core

© 2024 Biomedical Informatics Group, Dan L Duncan Comprehensive Cancer Center, Baylor College of Medicine